


## Summary

|                                 |  |
|---------------------------------|--|
| <b>Name</b>                     | LILRB4/ILT3/CD85k  |
| <b>Purity</b>                   | Greater than 95% as determined by reducing SDS-PAGE  |
| <b>Endotoxin level</b>          | <1 EU/μg as determined by LAL test.  |
| <b>Construction</b>             | Recombinant Cynomolgus Leukocyte immunoglobulin-like receptor subfamily B member 4 is produced by our Mammalian expression system and the target gene encoding Gln22-Glu259 is expressed with a 6His tag at the C-terminus.  |
| <b>Accession #</b>              | XM_015441712.1   |
| <b>Host</b>                     | Human cells  |
| <b>Species</b>                  | Cynomolgus   |
| <b>Predicted Molecular Mass</b> | 26.9 kDa   |
| <b>Formulation</b>              | Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4  |
| <b>Shipping</b>                 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.   |
| <b>Stability&amp;Storage</b>    | Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.   |
| <b>Reconstitution</b>           | Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |

## SDS-PAGE image



**Product Name: Recombinant Cynomolgus LILRB4 (C-6His)**  
**Catalog #: PHV2443**



---

## Background

### Alternative Names

Leukocyte immunoglobulin-like receptor subfamily B member 4; CD85 antigen-like family member K; Immunoglobulin-like transcript 3 (ILT-3); Leukocyte immunoglobulin-like receptor 5 (LIR-5); Monocyte inhibitory receptor HM18; CD85k; LILRB4; ILT3; LIR5

### Background

Leukocyte Immunoglobulin-like Receptor Subfamily B Member 4 (LILRB4/CD85k/ILT3) is an approximately transmembrane glycoprotein that negatively regulates immune cell activation. LILRB4 consists of a 215 amino acid (aa) extracellular domain with two Ig-like domains, a 22 aa transmembrane segment, and a 75 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM). Within the ECD, LILRB4 shares 45% and 77% aa sequence identity with human and rat LILRB4, respectively. Alternative splicing of LILRB4 generates a potentially soluble isoform that lacks the transmembrane segment. LILRB4 is expressed on dendritic cells (DC), monocytes, macrophages, and vascular endothelial cells (EC). Ligation of LILRB4 triggers ITIM-mediated inhibition of cell-activating signaling, leading to enhanced immune tolerance and reduced allogeneic graft rejection. Soluble LILRB4 induces the differentiation of CD8<sup>+</sup> T suppressor cells (Ts) that can inhibit the effector functions of CD4<sup>+</sup> Th cells and CD8<sup>+</sup> CTL. In turn, CD8<sup>+</sup> Ts cells induce LILRB4 up-regulation and a tolerogenic phenotype in monocytes, DC, and EC.

## Note

For Research Use Only , Not for Diagnostic Use.